- Filings
-
Holdings
-
Transcripts
- ETFs
- Insider
- Institutional
- Shorts
-
Profile
- Financials
Calidi Biotherapeutics (CLDI)
Company Profile
| Quarter (USD) | Jun 25 | Mar 25 | Dec 24 | Sep 24 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Annual (USD) | Dec 24 | Dec 23 | Dec 22 | Dec 21 | |
|---|---|---|---|---|---|
| Revenue | |||||
| Cost of revenue | |||||
| Operating income | |||||
| Operating margin | |||||
| Net income | |||||
| Net profit margin | |||||
| Cash on hand | |||||
| Change in cash | |||||
| Diluted EPS |
| Cash burn rate (est.) | Burn method: Change in cash | Burn method: Operating income | Burn method: FCF (opex + capex) | Last Q | Avg 4Q | Last Q | Avg 4Q | Last Q | Avg 4Q |
|---|---|---|---|---|---|---|
| Cash on hand (at last report) | 5.38 mm | 5.38 mm | 5.38 mm | 5.38 mm | 5.38 mm | 5.38 mm |
| Cash burn (monthly) | 1.80 mm | (no burn) | 1.92 mm | 1.68 mm | 1.63 mm | 1.87 mm |
| Cash used (since last report) | 7.92 mm | n/a | 8.44 mm | 7.40 mm | 7.15 mm | 8.20 mm |
| Cash remaining | -2.54 mm | n/a | -3.06 mm | -2.02 mm | -1.77 mm | -2.82 mm |
| Runway (months of cash) | -1.4 | n/a | -1.6 | -1.2 | -1.1 | -1.5 |
| 13F holders | Current |
|---|---|
| Total holders | 37 |
| Opened positions | 29 |
| Closed positions | 13 |
| Increased positions | 1 |
| Reduced positions | 1 |
| 13F shares | Current |
|---|---|
| Total value | 1.13 bn |
| Total shares | 15.29 mm |
| Total puts | 0.00 |
| Total calls | 0.00 |
| Total put/call ratio | – |
| Largest owners | Shares | Value |
|---|---|---|
| Allan Camaisa | 6.10 mm | $0.00 |
| Jackson Investment | 2.88 mm | $0.00 |
| First Light Acquisition | 2.58 mm | $0.00 |
| Scott Leftwich | 1.76 mm | $0.00 |
| Funicular Funds | 897.24 k | $1.08 mm |
| Geode Capital Management | 160.02 k | $184.02 mm |
| Millennium Management | 136.14 k | $156.56 mm |
| HighTower Advisors | 102.28 k | $117.62 mm |
| CPR Investments | 101.00 k | $116.15 mm |
| Drive Wealth Management | 90.00 k | $103.50 mm |
| Date | Owner | Security | Transaction | Code | Indirect | 10b5-1 | $Price | #Shares | $Value | #Remaining |
|---|---|---|---|---|---|---|---|---|---|---|
| 3 Sep 25 | Eric E Poma | Stock Options Common stock | Grant | Acquire A | No | No | 1.58 | 10,000 | 15.80 k | 10,000 |
| 3 Sep 25 | Santidrian Antonio Fernandez | Stock Options Common stock | Grant | Acquire A | No | No | 1.58 | 35,000 | 55.30 k | 35,000 |
| 3 Sep 25 | Jackson Andrew C. | Stock Options Common stock | Grant | Acquire A | No | No | 1.58 | 30,000 | 47.40 k | 30,000 |
| 21 Aug 25 | Eric E Poma | Common Stock | Buy | Acquire P | No | No | 2 | 25,000 | 50.00 k | 25,000 |
| 21 Aug 25 | Eric E Poma | Warrant Common stock | Buy | Acquire P | No | No | 2 | 25,000 | 50.00 k | 25,000 |
| 21 Aug 25 | Schoeneck James A | Common Stock | Buy | Acquire P | No | No | 2 | 75,000 | 150.00 k | 76,134 |
| 21 Aug 25 | Schoeneck James A | Warrant Common stock | Buy | Acquire P | No | No | 2 | 75,000 | 150.00 k | 75,000 |